RESUMEN
ObjectivesNo data were available about in-flight transmission of SARS-CoV-2. Here, we report an in-flight transmission cluster of COVID-19 and describe the clinical characteristics of these patients. MethodsAfter a flight, laboratory-confirmed COVID-19 was reported in 12 patients. Ten patients were admitted to the designated hospital. Data were collected from 25th January to 28th February 2020. Clinical information was retrospectively collected. ResultsAll patients are passengers without flight attendants. The median age was 33 years, and 70% were females. None was admitted to intensive care unit, and no patients succumbed through 28th February. The median incubation period was 3.0 days and from illness onset to hospital admission was 2 days. The most common symptom was fever. Two patients were asymptomatic and negative for chest CT scan throughout the disease courses. On admission, initial RT-PCR were positive in 9 patients, however initial chest CT were positive in only half patients. The median lung "total severity score" of chest CT was 6. Notably, "Crazy-Paving" pattern, pleural effusion, and ground-glass nodules were also seen. ConclusionIt is potential for COVID-19 transmission by airplane, but the symptoms are mild. Passengers and attendants must be protected during the flight.
RESUMEN
Objective To explore the possible effects of methyl methanesulfonate sensitive 2(MMS2)in the process of angiotensin Ⅱ inducing differentiation of neural stem cells (NSCs) into dopaminegic phenotype neurons. Methods NSCs were isolated from the brain of newborn rats and were cultured in the serum-free medium.Identification of neural precursor cells was done by Nestin immunocyt ochemical staining. Then the second generation of NSCs was divided into the following six groups: A, control; B, AⅡ; C, AT1 antagonist ZD7155; D, ZD7155+AⅡ; E, AT2 antagonist PD123319; F, PD123319+AⅡ. The detection of expression of MMS2 and TH mRNA level was done by real-time PCR. The silence of the expression of MMS2 in NSCs was brought about via the transfection of MMS2-siRNA, and then the NSCs were induced to differentiate into dopaminegic neurons. The expression of TH mRNA level in the cells of the groups after transfection was detected by real-time PCR. Results Nestin-positive cells were observed in suspended growth in the medium.Real-Time PCR revealed that the MMS2 and TH mRNA expression of group B and D were significantly higher than that of the control group(P<0.05), There was no significant difference in MMS2 and TH mRNA expression between group C, E, F and the control, respectively. Conclusion AⅡ increased the expression of MMS2 mRNA in NSCs and induced the differentiation of NSCs into DA neurons via AT2 recepter. MMS2 may play important roles in the process of angiotensin Ⅱ inducing NSCs to differentiate into dopaminergic neurons.
RESUMEN
Parkinson's disease(PD) is a kind of degenerative disease caused by both genetic and environ-mental factors. Concerning these two factors, various animal models for parkinson's disease were made for the study. Transgenic animal models were made by the method of microinjection, electronic perforation, particle bom-bardment, virus vector transfection and so on, which can express exogenous target gene. These models imitated the process of Parkinson's desease induced by virulence gene and provided a powerful tool for investigation on e-tiopathogenesis, gene therapy and medical intervention. In this article, we reviewed the progress of genetic models associated with PD and theirs contribution to PD research.
RESUMEN
Parkinson’s disease is resulted from the progressive degeneration and from the loss of dopaminergic neurons in Substantia Nigra. Current researches focuson the optimum conditions in vivo and in vitro associating the differentiation as well as survival of dopaminergic neurons,in order to get sufficient dopaminergic neurons for cell-replacement therapy in Parkinson’s disease. This paper reviewed influential factors of neural stem cells differentiate into dopaminergic neurons in vivo and in vitro.
